- Home
- ZYBT vs SLRX Comparison
ZYBT vs SLRX Comparison
Compare ZYBT & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- SLRX
- Stock Information
- Founded
- ZYBT 2004
- SLRX N/A
- Country
- ZYBT China
- SLRX United States
- Employees
- ZYBT N/A
- SLRX N/A
- Industry
- ZYBT
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- SLRX Health Care
- Exchange
- ZYBT NYSE
- SLRX Nasdaq
- Market Cap
- ZYBT 340.3M
- SLRX 1.8M
- IPO Year
- ZYBT 2025
- SLRX N/A
- Fundamental
- Price
- ZYBT $5.58
- SLRX $0.68
- Analyst Decision
- ZYBT
- SLRX
- Analyst Count
- ZYBT 0
- SLRX 0
- Target Price
- ZYBT N/A
- SLRX N/A
- AVG Volume (30 Days)
- ZYBT 223.5K
- SLRX 3.6M
- Earning Date
- ZYBT 07-03-2025
- SLRX 08-08-2025
- Dividend Yield
- ZYBT N/A
- SLRX N/A
- EPS Growth
- ZYBT N/A
- SLRX N/A
- EPS
- ZYBT 0.03
- SLRX N/A
- Revenue
- ZYBT $25,531,367.00
- SLRX N/A
- Revenue This Year
- ZYBT N/A
- SLRX N/A
- Revenue Next Year
- ZYBT N/A
- SLRX N/A
- P/E Ratio
- ZYBT $172.98
- SLRX N/A
- Revenue Growth
- ZYBT N/A
- SLRX N/A
- 52 Week Low
- ZYBT $3.50
- SLRX $0.45
- 52 Week High
- ZYBT $14.30
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- SLRX 37.80
- Support Level
- ZYBT N/A
- SLRX $0.64
- Resistance Level
- ZYBT N/A
- SLRX $0.90
- Average True Range (ATR)
- ZYBT 0.00
- SLRX 0.11
- MACD
- ZYBT 0.00
- SLRX -0.03
- Stochastic Oscillator
- ZYBT 0.00
- SLRX 6.92
About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.